Overview An Open Label Study of the Effects of SHR1459 in NMOSDs Patients Status: Active, not recruiting Trial end date: 2022-09-30 Target enrollment: Participant gender: Summary This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs. Phase: Phase 2 Details Lead Sponsor: Reistone Biopharma Company Limited